The detection and significant downregulation of GUCY2C transcripts in the LDAA and AZA patient groups raises questions about the potential of GUCY2C as a marker of IBD disease status and response to therapy with thiopurines or other drugs. This evidence concerns the gene GUCY2C and inflammatory bowel disease.